Alera Bio Announces Exclusive Licensing Agreement with BLA Technology to Expand Thyroid Hormone Intellectual Property Portfolio
Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. - April 09, 2026
Alera Bio Appoints Andrew Eisen, MD, PhD, as Chief Scientific Officer
Alera Bio has appointed Andrew Eisen, MD, PhD, as Chief Scientific Officer, bringing over 20 years of experience in translational medicine and clinical development. With deep expertise in neuroscience, metabolic disease, and myelination, Dr. Eisen will lead the advancement of Alera’s lead program, AB-101, and help drive its mission to develop transformative therapies for patients with severe neurological disorders, including MCT-8 deficiency. - April 08, 2026
Alera Bio Announces Appointment of Board of Directors
Alera Bio, a Chicago-based biotech developing therapies for rare neuroendocrine and neurological disorders, announced its inaugural Board of Directors. The board includes leaders in biopharma, clinical practice, and finance, such as Stephen Hill, Mark Prygocki, Renny Griffith, and Cassius Coleman. Their combined expertise will guide Alera Bio as it advances AB-101 for MCT-8 deficiency, an FDA-designated Rare Pediatric Disease therapy. - November 11, 2025
Alera Bio Announces Appointment of Executive Leadership Team
Alera Bio announced its executive team: Philip Vorhies (CEO), Peter Thomson (CFO), Eric Floyd, PhD (CRO), and Caitlin Murray (GC), supported by expert consultants. Founder Frank Jaeger noted their strength in biotech, finance, regulatory, and legal, positioning Alera to advance AB-101 for MCT-8 deficiency, a rare neurological disorder with FDA Rare Pediatric Disease designation. - September 26, 2025
Alera Bio Launches Lead Rare Disease Program with Exclusive Rights to MCT-8 Deficiency Therapy
Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in place. - September 18, 2025
Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders
Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. - July 03, 2025